- NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
- AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
- U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
- Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
Key statistics
On Monday, AbbVie Inc (ABBV:NYQ) closed at 161.28, -11.82% below its 52-week high of 182.89, set on Mar 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 161.28 |
---|---|
High | 162.57 |
Low | 160.80 |
Bid | 161.10 |
Offer | 161.45 |
Previous close | 160.75 |
Average volume | 5.13m |
---|---|
Shares outstanding | 1.77bn |
Free float | 1.76bn |
P/E (TTM) | 48.47 |
Market cap | 287.36bn USD |
EPS (TTM) | 3.36 USD |
Annual div (ADY) | 6.20 USD |
---|---|
Annual div yield (ADY) | 3.86% |
Div ex-date | Apr 12 2024 |
Div pay-date | May 15 2024 |
Data delayed at least 15 minutes, as of May 13 2024 21:10 BST.
More ▼